Navigation Links
Bronchial thermoplasty – a promising treatment for asthmatic

According to Canadian researchers, asthma patients’ quality of life can be drastically improved by removing the muscle tissue (by heating it) in the hyperactive airways. This// reduces the intensity of the problem.

The investigators announced this during CHEST 2006, the annual meeting of the American College of Chest Physicians. The Asthma Intervention Research trial was conducted on 108 patients of an average age of 39.4 years who had poorly controlled moderate-to-severe asthma. Even the best drug therapy with corticosteroids and long-acting beta-agonists could not control their asthma.

FEV1 (forced expiration volume in 1 second) is a test generally used to measure lung function. The patients had FEV1 levels 60-80% of normal at the beginning of the study.

Dr. Michel Laviolette of Laval University in Sainte-Foy, Quebec, and his colleagues divided the patients at random into 2 groups, the control group and the group that would undergo bronchial thermoplasty. In this procedure, a catheter with a thermal energy tip reduces smooth muscle mass in all reachable airways. Nearly 45 activations were delivered in every session that lasted 30 minutes. Three such sessions of thermoplasty were performed. The patients were then assessed 3, 6 and 12 months after thermoplasty and the FEV1 was also measured each time.

"Patients also refrained from using long-acting beta-agonists for two weeks before each assessment to destabilize disease and capture true disease activity and get a better assessment of the efficacy of thermoplasty," Laviolette explained.

"There was a 50-percent reduction in exacerbation rates in the thermoplasty group compared with the controls, " Laviolette announced. "The need for asthma medication was also significantly reduced and quality of life scores were significantly higher in thermoplasty patients.

"There was a significant change in disease exacerbation in thermoplasty patients. There was no cha
'"/>




Page: 1 2

Related medicine news :

1. New Drug for Bronchial Asthma
2. PCR emerging as a promising technique for Diagnosing Urinary Tuberculosis
3. Experimental treatment for Ebola Virus Shows promising results in mice
4. A promising treatment for wart removal
5. Hepatitis shots is promising
6. Research Ethics Requirements Compromising Quality of Health Research
7. Thyroid hormone treatment hastens recovery after cardiac surgery
8. Feeding channel created by malaria parasite - a new target for malaria treatments
9. Now umbilical cord helps in stroke treatment.
10. Now AIDS treatment comes dirt-cheap
11. Breast cancer treatment to be determined by gene test
Post Your Comments:
(Date:7/23/2008)...to Meet the Financing Needs of European and ...-, NEW YORK, July 24 /PRNewswire/ -- Paul Capital... has been promoted to Partner. Based in Paul,Capit... sourcing,evaluating and negotiating European and... Paul Capital Healthcare funds., "Since he joined...
(Date:7/23/2008)... /PRNewswire/ -- MediVoice(R), LLC, the,world,s fi...and,e-Prescribing, has formed a strategic partners...ractive, web-based, patient-centered health record...integrate and market its,mobile voice-activation s...) system., "MediVoice is pleased to develop a str...
(Date:7/23/2008)...wire/ -- Philip J. Dwyer, president and CEO,of the... before the U.S.,Senate Health, Education, Labor, ...nd Families today to call for increased funds for ...ed at YMCAs across the nation, that will,help redu...on behalf of the more than 2,600 YMCAs, that -- fo...
(Date:7/23/2008)...gration and Naturalization ready at Passport ...y 23 /PRNewswire/ -- New vaccine requirements will...sa for entry into the U.S. and,anyone seeking adju...ts,must show proof of vaccinations against vaccine...Advisory Committee on Immunization Practices.,Pass...
Breaking Medicine News(10 mins):Health News:Paul Capital Partners Promotes Ken Macleod To Partner 2Health News:Paul Capital Partners Promotes Ken Macleod To Partner 3Health News:MediVoice(R) Partners With VisionTree(R) to Integrate Its Voice-Activated e-Prescribing Solution Into VisionTree's VTOC(TM) Web-Based Patient Management System 2Health News:MediVoice(R) Partners With VisionTree(R) to Integrate Its Voice-Activated e-Prescribing Solution Into VisionTree's VTOC(TM) Web-Based Patient Management System 3Health News:YMCA Calls on Senate to Fund Community-Based Solutions to Address Childhood Obesity Crisis 2Health News:YMCA Calls on Senate to Fund Community-Based Solutions to Address Childhood Obesity Crisis 3Health News:USCIS Tightens Vaccination Requirements 2
... Health says many smokers are yet to understand th...warning pictures are an effective// way to get the...r of Health, Damien O'Connor, today launched a pro...ackets. The Ministry wants feedback on whether he...
...ol of Business (ISB) Tuesday signed a memorandum o...derabad-based real estate company, to establish// ...n studies'. This is said to be the first such st...chool in India. It is also the first research cha...
... found a gene that increased Type 2 diabetes in ov...d new treatment for the condition in humans. // T...ition, with an estimated 16 million Americans affl...en, the development of the disease is caused by ob...
...high on fiber is perhaps the first thing that doct...offsetting hemorrhoids. // Hemorrhoids, a conditio...n and around the anus that can give rise to bleedi...erican Society of Colon and Rectal Surgeons, hemor...
Other Medicine News:Health News:New Zealand To Issue Graphic Warnings In Cigarette Packs 2
(Date:7/23/2008)...apy to Treat the Disease -, WAYNE, N.J. and EMERY...ayer HealthCare Pharmaceuticals and Onyx Pharmaceu...he New England Journal of Medicine published,resul...) (sorafenib),tablets decreased the absolute risk ...le hepatocellular carcinoma (HCC), or liver cancer...
(Date:7/23/2008)...e/ -- The following was,released by the U.S. Depar...er Smith, and Members of the Committee.,Thank you ...peared before this Committee almost six months ago...lented and dedicated professionals,at the Justice ...ome to,appreciate that much more deeply their serv...
(Date:7/23/2008)...Code BioPharmaceutics, Inc.,an emerging biopharma...,results demonstrating the utility of their lead d...chronic blood disorder paroxysmal nocturnal,hemogl...nted at the XXII,International Complement Workshop...only treatment currently available for PNH patient...
(Date:7/22/2008)...FirstCall/ -- Following a,thorough review that con...euticals Limited (ASX: PGL; Nasdaq: PGLA) today an... study in liver cancer. Progen confirmed,its strat...f compounds and,the company will actively seek to ...ough Merger & Acquisition activity., The strategi...
Breaking Medicine Technology:The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3New Lung Association Study Shows 24142 Billion Benefit of Converting to Zero Emission Vehicles by 2030 14836 1New Lung Association Study Shows 24142 Billion Benefit of Converting to Zero Emission Vehicles by 2030 14836 2New Lung Association Study Shows 24142 Billion Benefit of Converting to Zero Emission Vehicles by 2030 14836 3New Lung Association Study Shows 24142 Billion Benefit of Converting to Zero Emission Vehicles by 2030 14836 4NHS Choices Launches New Fitness Section 14834 1Admins Support 65 25 More Pharma Operations Execs than Rule of Thumb Dictates 14832 1Admins Support 65 25 More Pharma Operations Execs than Rule of Thumb Dictates 14832 2Monkey Brain Gives Clues to Human Interaction 14831 1Monkey Brain Gives Clues to Human Interaction 14831 2
.../PRNewswire/ -- Novagali Pharma, an,emerging ophth...lmology, announces today positive results from the...n suffering from Vernal,Keratoconjunctivitis (VKC)...ymptoms and signs of disease improved in patients,...y to Vekacia(R),was excellent. , VKC is a severe f...
...Apr 4, 2007 - CytRx Corporation,(NASDAQ:CYTR) toda...stroke studies indicating that CytRx,s lead drug c... recovery of sensory and,motor function in an expe...was withheld as long as 48 hours after stroke was,...nical data,announced by CytRx in December 2006. Or...
Other Medicine Technology:Novagali Pharma Announces Positive Vekacia Clinical Results From,Pivotal Phase III Trial in Vernal Keratoconjunctivitis 2CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 2CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 3CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 4CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 5
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations.
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations.
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations.
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations.
Medicine Products: